DNA-Guided drug switch could improve GIST treatment

NCT ID NCT05366816

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether DNA changes in the KIT gene can predict how well patients with advanced gastrointestinal stromal tumor (GIST) respond to two standard drugs, sunitinib and regorafenib. About 48 adults whose GIST has worsened on imatinib will receive the drugs in sequence. The goal is to see if personalized drug selection based on DNA improves response rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sunitinib and regorafenib
What this could lead to: If successful, this could show that DNA testing helps doctors choose the right drug for each GIST patient, improving treatment outcomes.
What could go wrong: This is a small, early-phase trial with only 48 participants. The approach may not work for everyone, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMORS

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.